Impact of Pharmacist Managed PAH Program on Medication Adherence

This research article assesses the effectiveness of a Pharmacist-Led Pulmonary Arterial Hypertension (PAH) program on medication adherence for patients using treprostinil (Tyvaso). The study compares a cohort of 2,555 patients enrolled in the PAH program with a control group of 332 non-enrolled patients, analyzing various patient characteristics such as age, sex, geographic region, and Social Vulnerability Index (SVI). The objective is to evaluate the program's impact on medication adherence measured by the proportion of days covered (PDC) over a 12-month follow-up period. Results indicate that the program has a broad geographic and sociodemographic reach, engaging patients from both rural and urban communities. Findings reveal that enrollment in the PAH program is associated with improved adherence to treprostinil, with a mean PDC of 0.87 compared to 0.78 in the control group. The study highlights the potential of targeted pharmacy programs to enhance medication adherence and improve patient outcomes in managing complex conditions like PAH.